PT - JOURNAL ARTICLE AU - Rebeca C. Falcão AU - Michael Otterstatter AU - May A. Ahmed AU - Michelle Spencer AU - Sarafa Iyaniwura AU - Naveed Z. Janjua AU - Geoff McKee AU - Michael A. Irvine TI - Impact of routine asymptomatic screening on COVID-19 incidence in a highly vaccinated university population AID - 10.1101/2021.10.18.21265057 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.18.21265057 4099 - http://medrxiv.org/content/early/2021/10/20/2021.10.18.21265057.short 4100 - http://medrxiv.org/content/early/2021/10/20/2021.10.18.21265057.full AB - Background With the return of in-person classes, an understanding of COVID-19 transmission in vaccinated university campuses is essential. Given the context of high anticipated vaccination rates and other measures, there are outstanding questions of the potential impact of campus-based asymptomatic screening.Methods We estimated the expected number of cases and hospitalizations in one semester using rates derived for British Columbia (BC), Canada up to September 15th, 2021 and age-standardizing to a University population. To estimate the expected number of secondary cases averted due to routine tests of unvaccinated individuals in a BC post-secondary institution, we used a probabilistic model based on the incidence, vaccination effectiveness, vaccination coverage and R0. We examined multiple scenarios of vaccine coverage, screening frequency, and pre-vaccination R0.Results For one 12 week semester, the expected number of cases is 67 per 50,000 for 80% vaccination coverage and 37 per 50,000 for 95% vaccination coverage. Screening of the unvaccinated population averts an expected 6-16 cases per 50,000 at 80% decreasing to 1-2 averted cases per 50,000 at 95% vaccination coverage for weekly to daily screening. Further scenarios can be explored using a web-based application.Interpretation Routine screening of unvaccinated individuals may be of limited benefit if vaccination coverage is 80% or greater within a university setting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by British Columbia Centre for Disease Control.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the University of British Columbia Behavioral Research Ethics Board (No: H20-02097).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCOVID-19 confirmed case data used in this study is not publicly available. UBC demographics data are available publicly at links given in the manuscript.